Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) Invested Capital (2023 - 2025)

Historic Invested Capital for Inhibrx Biosciences (INBX) over the last 3 years, with Q3 2025 value amounting to $136.7 million.

  • Inhibrx Biosciences' Invested Capital fell 2337.69% to $136.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.7 million, marking a year-over-year decrease of 2337.69%. This contributed to the annual value of $133.6 million for FY2024, which is 20706.85% up from last year.
  • As of Q3 2025, Inhibrx Biosciences' Invested Capital stood at $136.7 million, which was down 2337.69% from $167.8 million recorded in Q2 2025.
  • Inhibrx Biosciences' Invested Capital's 5-year high stood at $219.4 million during Q2 2024, with a 5-year trough of $43.5 million in Q4 2023.
  • Over the past 3 years, Inhibrx Biosciences' median Invested Capital value was $167.8 million (recorded in 2025), while the average stood at $153.2 million.
  • Per our database at Business Quant, Inhibrx Biosciences' Invested Capital surged by 20706.85% in 2024 and then crashed by 2348.95% in 2025.
  • Inhibrx Biosciences' Invested Capital (Quarter) stood at $43.5 million in 2023, then surged by 207.07% to $133.6 million in 2024, then grew by 2.37% to $136.7 million in 2025.
  • Its last three reported values are $136.7 million in Q3 2025, $167.8 million for Q2 2025, and $193.1 million during Q1 2025.